ALS News Today2d
Zydus cleared to begin US trial of oral therapy usnoflast for ALS
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Hosted on MSN18d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
The drug was investigated as part of the HEALEY ALS Platform trial. Its primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised ...
Business Insider20d
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Seeking Alpha17d
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].
Saint Louis University3y
Saint Louis University ALS Center of Excellence
These research centers share data and collaborate on clinical trials. One such clinical trial is the HEALEY ALS Platform Trial, a multi-center, multi-regimen clinical trial evaluating the safety and ...
Adelaide Now1mon
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
He said with the OMPD milestone Neurizon was well positioned to advance NUZ-001 through the phase II/III HEALEY ALS Platform Trial, starting patient enrolment in early H1 CY25. “Our goal remains ...